Journal article

A Randomized Study of Adefovir Dipivoxil in Place of HBIG in Combination with Lamivudine As Post-Liver Transplantation Hepatitis B Prophylaxis

Peter W Angus, Scott J Patterson, Simone J Strasser, Geoffrey W McCaughan, Edward Gane

Hepatology | JOHN WILEY & SONS INC | Published : 2008


UNLABELLED: Prior to effective prophylaxis, liver transplantation for hepatitis B virus (HBV)-related disease was frequently complicated by recurrence, which could be severe and rapidly progressive. Combination hepatitis B immunoglobulin (HBIG) and lamivudine prophylaxis reduces this rate of recurrence to <5% at 5 years; however, HBIG administration is costly and inconvenient. We conducted a multicenter randomized study of adefovir dipivoxil substitution for low-dose intramuscular (IM) HBIG in patients without HBV recurrence at least 12 months posttransplantation for HBV-related disease. Thirty-four patients were randomized, 16 to adefovir (1 patient withdrew consent at 3 months and is not c..

View full abstract

University of Melbourne Researchers